China-based JW Therapeutics (HKG: 2126) has announced the initiation of a clinical study for its Carteyva (relmacabtagene autoleucel injection) in the treatment of first-line high-risk large B-cell lymphoma. A significant milestone was reached with the completion of reinfusion therapy for the first patient.
Previous Study Outcomes and Current Trial Design
The pivotal RELIANCE study previously demonstrated that Carteyva exhibited good safety and excellent efficacy in patients with recurrent/refractory large B-cell lymphoma who had undergone at least second-line treatment. Building on these results, the current open, one-arm, multi-center, investigator-initiated trial (IIT) in China is designed to evaluate the drug’s effectiveness and safety as a first-line treatment for adult patients with high-risk large B-cell lymphoma.
About Carteyva
Relmacabtagene autoleucel is an autologous anti-CD19 CAR-T cell immunotherapy product independently developed by JW Therapeutics. It has already been approved in China for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy, as well as for adult patients with follicular lymphoma that is refractory or has relapsed within 24 months of second-line or above systemic treatment (r/r FL). The initiation of this new clinical study marks a further expansion of the potential therapeutic applications of Carteyva.-Fineline Info & Tech
